These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 15593198

  • 1. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH.
    Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
    [Abstract] [Full Text] [Related]

  • 2. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL.
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R, Wang O, Satterwhite J, Mitlak B.
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [Abstract] [Full Text] [Related]

  • 5. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis.
    Silverman SL, Piziak VK, Chen P, Misurski DA, Wagman RB.
    J Rheumatol; 2005 Dec; 32(12):2405-9. PubMed ID: 16331772
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

  • 10. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 11. Impact of recent fracture on health-related quality of life in postmenopausal women.
    Brenneman SK, Barrett-Connor E, Sajjan S, Markson LE, Siris ES.
    J Bone Miner Res; 2006 Jun 10; 21(6):809-16. PubMed ID: 16753011
    [Abstract] [Full Text] [Related]

  • 12. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep 10; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 13. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.
    Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J.
    J Bone Miner Res; 2000 Jul 10; 15(7):1384-92. PubMed ID: 10893688
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 10; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL, Shen W, Minshall ME, Xie S, Moses KH.
    J Rheumatol; 2007 Jan 10; 34(1):140-4. PubMed ID: 17216681
    [Abstract] [Full Text] [Related]

  • 16. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.
    J Bone Joint Surg Am; 2009 Jun 10; 91(6):1329-38. PubMed ID: 19487509
    [Abstract] [Full Text] [Related]

  • 17. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 10; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 18. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM.
    Aging Clin Exp Res; 2007 Jun 10; 19(3 Suppl):21-3. PubMed ID: 18180603
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D, Stoykov I, Lems WF, Langdahl BL, Ljunggren Ö, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Marin F.
    J Rheumatol; 2012 Mar 10; 39(3):600-9. PubMed ID: 22247365
    [Abstract] [Full Text] [Related]

  • 20. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
    Maugeri D, Russo E, Luca S, Leotta C, Mamazza G, Sorace R, Rizzotto M, Manuele S, Fiore V, Taverna G, Castiglia B, Calitro M.
    Arch Gerontol Geriatr; 2009 Mar 10; 49(1):35-8. PubMed ID: 18555544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.